R
Raymond Snyder
Researcher at St. Vincent's Health System
Publications - 65
Citations - 6626
Raymond Snyder is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 25, co-authored 64 publications receiving 6302 citations. Previous affiliations of Raymond Snyder include University of Texas MD Anderson Cancer Center & University of Texas System.
Papers
More filters
Journal ArticleDOI
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
M Marty,Francesco Cognetti,Dominique Maraninchi,Raymond Snyder,Louis Mauriac,Michèle Tubiana-Hulin,Stephen Chan,David Grimes,Antonio Antón,Anna Lluch,John Kennedy,Kenneth J. O'Byrne,Pierfranco Conte,Michael D. Green,Carol Ward,Karen Mayne,Jean-Marc Extra +16 more
TL;DR: Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
Journal ArticleDOI
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jänicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,Mercedes Lassus,J. Arnold Verbeek,Beatrix Staffler,H. A. Chaudri-Ross,Margaret Dugan +20 more
TL;DR: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate, and its results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Journal ArticleDOI
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jaenicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,H. A. Chaudri-Ross,Raquel Lang,Peter J. Wyld,Ajay Bhatnagar +19 more
TL;DR: This study documents the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Journal ArticleDOI
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.
Alan S. Coates,Val Gebski,James F. Bishop,Peter N. Jeal,R. L. Woods,Raymond Snyder,Martin H.N. Tattersall,M. J. Byrne,V J Harvey,Grantley Gill,John Simpson,Roslyn M. Drummond,Judy Browne,Rodney van Cooten,John F. Forbes +14 more
TL;DR: Continuous chemotherapy is better than intermittent chemotherapy for advanced breast cancer, as tested, and changes in the quality of life were independent prognostic factors in proportional-hazards models of subsequent survival.
Journal ArticleDOI
Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials
Bernhard C. Pestalozzi,David Zahrieh,Elizabeth Mallon,Barry A. Gusterson,Karen N. Price,Richard D. Gelber,Stig Holmberg,Jurij Lindtner,Raymond Snyder,Beat Thürlimann,Elizabeth Murray,Giuseppe Viale,Monica Castiglione-Gertsch,Alan S. Coates,Aron Goldhirsch +14 more
TL;DR: ILC is more than a histologic variant of breast cancer, and the diagnosis of ILC carries distinct prognostic and biologic implications.